Table 2.
Parameter | Model 1—peak clusters | Model 2—clinical parameters | Model 3—combined | ||||||
---|---|---|---|---|---|---|---|---|---|
HR | (95% CI) | P value | HR | (95% CI) | P value | HR | (95% CI) | P value | |
Peak cluster | |||||||||
m/z 3073 | 3.17 | (2.03–4.96) | <0.001 | 2.48 | (1.78–3.48) | <0.001 | |||
m/z 3274 | 10.18 | (1.99–52.01) | 0.005 | 11.71 | (2.05–66.90) | 0.006 | |||
m/z 4405 | 0.02 | (0.01–0.25) | 0.003 | 0.01 | (0.01–0.17) | 0.001 | |||
m/z 7973 | 0.05 | (0.01–0.48) | 0.010 | 0.24 | (0.03–1.78) | 0.160 | |||
Treatment | |||||||||
CONV | 1 | – | – | 1 | – | – | |||
HD | 1.59 | (0.86–2.95) | 0.140 | 2.48 | (1.24–4.98) | 0.011 | |||
Age | |||||||||
<40 years | 1 | – | – | 1 | – | – | |||
≥40 years | 0.44 | (0.22–0.88) | 0.021 | 0.35 | (0.16–0.74) | 0.006 | |||
No. of LN+ | |||||||||
≥10 | 1 | – | – | 1 | – | – | |||
4–9 | 0.44 | (0.23–0.84) | 0.012 | 0.37 | (0.19–0.72) | 0.003 | |||
PR status | |||||||||
PR(−) | 1 | – | – | 1 | – | – | |||
PR(+) | 0.40 | (0.22–0.73) | 0.003 | 0.28 | (0.14–0.55) | < 0.001 |
CONV conventional dose arm, HD high-dose arm, LN+ number of positive lymph nodes, PR progesterone receptor status positive (+) and negative (−)